Hayato Mizuta

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes

K. Furugaki, Takaaki Fujimura, Y. Yoshimura, 2023, NPJ precision oncology.

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer

Ryohei Katayama, H. Hayashi, K. Furugaki, 2024, NPJ precision oncology.

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

A. Drilon, H. Pelish, M. Shair, 2024, Cancer discovery.